-
Views
-
Cite
Cite
Didier Neau, Pascale Trimoulet, Maria Winnock, Anne Rullier, Brigitte Le Bail, Denis Lacoste, Jean-Marie Ragnaud, Paulette Bioulac Sage, Marie-Edith Lafon, Geneviève Chêne, Michel Dupon, ROCO Study Group, Comparison of 2 Regimens that Include Interferon-α-2a plus Ribavirin for Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus—Coinfected Patients, Clinical Infectious Diseases, Volume 36, Issue 12, 15 June 2003, Pages 1564–1571, https://doi.org/10.1086/375067
Close - Share Icon Share
Abstract
An open-label, randomized trial was conducted to compare the efficacy and safety of 2 regimens of interferon-α-2a (IFN-α-2a) plus ribavirin for management of chronic hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)–coinfected patients. Sixty-eight patients were randomized to receive IFN-α-2a at a dosage of either (1) 6 MU given 3 times per week for 24 weeks, followed by 3 MU 3 times per week for an additional 24 weeks (group A; 31 patients); or (2) 9 MU per day for 2 weeks, followed by 3 MU per day for 22 weeks, followed by 3 MU 3 times per week for 24 weeks (group B; 37 patients). Ribavirin was added at week 16 of therapy if HCV RNA remained detectable at week 12. Sustained virological response was achieved in 10 patients (15%; 6 in group A and 4 in group B). HCV genotypes 2 or 3 and a decrease in the HCV load of ≤3 log10 copies/mL between inclusion and week 4 were associated with virological response. In conclusion, the combination of conventional IFN-α-2a and ribavirin has poor virological efficacy in HCV-HIV–coinfected patients.
